v3.26.3
Segment information
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment information Segment information
As of September 30, 2026, the Company operated in one operating segment, and therefore one reportable segment, focused on the research and development of YB-101, its product candidate for the treatment of GD and TED. This determination, that the Company operated as a single operating segment, is consistent with the financial information regularly reviewed by the Company’s Chief Operating Decision Maker (“CODM”) for purposes of evaluating performance, allocating resources, and planning and forecasting for future periods. The Company’s Chief Executive Officer was the CODM.
The accounting policies for the single operating segment are the same as those described in "Note 2 - Significant accounting policies". The CODM uses net loss that is reported on the unaudited condensed consolidated statement of operations to allocate resources (including employees, property, and financial resources), predominantly during the annual budget and forecasting process. The Company’s CODM views specific program spend within research and development expenses as well as overall general and administrative expenses as significant segment expenses. As a pre-commercial company, the CODM also considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and deciding the level of investment in the Company’s operating and capital allocation activities. Further, the measure of segment assets is reported on the unaudited condensed consolidated balance sheet as total consolidated assets. All long-lived assets are held in the United States.
The following table presents the Company's segment significant expenses regularly reviewed by the CODM and net loss for the three and nine months ended September 30, 2026:
Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)20262026
Operating expenses:
Research and development:
Clinical and external research and development costs$4,339 $9,444 
Personnel related838 1,890 
Other100 127 
General and administrative costs
Personnel related1,452 2,793 
Professional fees1,547 3,397 
Other*2,467 2,649 
Total operating expenses10,743 20,300 
Operating loss(10,743)(20,300)
Other income/(expenses):
Interest income925 1,225 
Other income, net94 94 
Total other income, net1,019 1,319 
Net loss$(9,724)$(18,981)

*Includes Merger-related expenses
Accordingly, the Company managed its operations as a single operating and reportable segment, and the unaudited condensed consolidated financial statements and notes thereto are presented as a single reportable segment.